Dorian Therapeutics is a YC- and VC-backed preclinical company developing small molecules aimed to reactivate stem cell pathways crucial for tissue regeneration. Focused on targeting key epigenetic regulators, Dorian is developing novel therapies for age-related diseases, including autoimmune diseases and osteoarthritis. The founders developed the initial concept at Stanford University before spinning out the technology to their Silicon Valley company.